Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia

JAMA

Volumn 304, Issue 24, 2010, Pages 2706-2715

  Gentles, Andrew J ^a   Plevritis, Sylvia K ^a   Majeti, Ravindra ^c,d   Alizadeh, Ash A ^b,c,d  

^a STANFORD UNIVERSITY   (United States)

^b Free University of Brussels   (United States)

^c Department of Hematology ^*  (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CELL MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASSOCIATION; BAALC GENE; CANCER STEM CELL; CANCER SURVIVAL; CEBPA GENE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FLT 3 GENE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; LEUKEMIA CELL; MICROARRAY ANALYSIS; NPM 1 GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; UNITED STATES;

EID: 78650444882     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1862     Document Type: Article

References (55)

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-1907.
2. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-1062.
3. Byrd JC, Mrózek K, Dodge RK, et al; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia. Blood. 2002;100(13):4325-4336.
4. Grimwade D, Walker H, Oliver F, et al; Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML. Blood. 1998;92(7): 2322-2333.
5. Mrózek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics. Blood. 2007;109(2):431-448.
6. Schlenk RF, Döhner K, Krauter J, et al; German- Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358(18):1909-1918.
7. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355(12):1253-1261.
8. Reya T, Morrison SJ, Clarke MF,Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-111.
9. Weissman I. Stem cell research. JAMA. 2005; 294(11):1359-1366.
10. Dick JE. Stem cell concepts renew cancer research. Blood. 2008;112(13):4793-4807.
11. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3 (7):730-737.
12. Majeti R, Becker MW, Tian Q, et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A. 2009;106(9):3396-3401.
13. Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy- resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315-1321.
14. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC- 1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267-273.
15. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98(9): 5116-5121.
16. Metzeler KH, Hummel M, Bloomfield CD, et al; Cancer and Leukemia Group B; German AML Cooperative Group. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112(10):4193-4201.
17. Tomasson MH, Xiang Z, Walgren R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood. 2008;111 (9):4797-4808.
18. Wilson CS, Davidson GS, Martin SB, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood. 2006;108(2):685-696.
19. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088-3091.
20. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058- 1066.
21. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105(11):4163-4169.
22. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults. Blood. 2010;115(3): 453-474.
23. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009:385-395.
24. Heagerty PJ, Lumley T, Pepe MS. Timedependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337-344.
25. Langer C, Radmacher MD, Ruppert AS, et al; Cancer and Leukemia Group B (CALGB). High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct geneexpression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia. Blood. 2008;111(11):5371-5379.
26. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-1628.
27. Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570-577.
28. Lee EJ, Pollak A, Leavitt RD, et al. Minimally differentiated acute nonlymphocytic leukemia. Blood. 1987;70(5):1400-1406.
29. Costello R, Mallet F, Chambost H, et al. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0). Leukemia. 1999;13 (10):1513-1518.
30. Cleary ML. Regulating the leukaemia stem cell. Best Pract Res Clin Haematol. 2009;22(4):483-487.
31. Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia- initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 2010;115(10):1976- 1984.
32. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemiainitiating cells. Blood. 2008;112(3):568-575.
33. van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11(18):6520-6527.
34. Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML. Blood. 2006;107(3):1166-1173.
35. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5(1):31-42.
36. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286-299.
37. van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110(7):2659-2666.
38. Bullinger L, Döhner K, Bair E, et al. Use of geneexpression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004; 350(16):1605-1616.
39. Nitta T, Takahama Y. The lymphocyte guard-IANs. Trends Immunol. 2007;28(2):58-65.
40. Guenther MG, Levine SS, Boyer LA, et al. A chromatin landmark and transcription initiation at most promoters in human cells. Cell. 2007;130(1):77-88.
41. Kook H, Lepore JJ, Gitler AD, et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest. 2003;112 (6):863-871.
42. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14(14):4500-4510.
43. Lodygin D, Menssen A, Hermeking H. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest. 2002;110(11):1717-1727.
44. Oshita AK, Rothstein G, Lonngi G. cGMP stimulation of stem cell proliferation. Blood. 1977;49 (4):585-591.
45. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breastcancer cells. N Engl J Med. 2007;356(3):217-226.
46. Gentles AJ, Alizadeh AA, Lee SI, et al. A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood. 2009;114(15):3158-3166.
47. Wong DJ, Liu H, Ridky TW, et al. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell. 2008;2(4):333-344.
48. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104): 818-822.
49. McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 2010;115(2):315-325.
50. Guzman ML, Li X, Corbett CA, et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4- thiadiazolidine, 3,5 dione (TDZD-8). Blood. 2007; 110(13):4436-4444.
51. Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009;16(4):281-294.
52. Hassane DC, Guzman ML, Corbett C, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 2008;111(12):5654-5662.
53. Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167-1174.
54. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med. 2010;2(14):14ps12.
55. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer. N Engl J Med. 2004;351 (27):2817-2826.